Amgen Inc Stock Today
| AMGN Stock | USD 325.28 3.37 1.05% |
Performance1 of 100
| Odds Of DistressLess than 6
|
Amgen is selling at 325.28 as of the 8th of November 2024; that is 1.05 percent increase since the beginning of the trading day. The stock's open price was 321.91. Amgen has only a 6 % chance of going through financial distress over the next few years but had a somewhat weak performance during the last 90 days. Note, on October 10, 2024, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Amgen Inc's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of June 1983 | Category Healthcare | Classification Health Care |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 537.53 M outstanding shares of which 9.37 M shares are presently shorted by private and institutional investors with about 4.62 trading days to cover. More on Amgen Inc
Moving against Amgen Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Amgen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Robert Bradway | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | Showing 3 out of 7 themes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Dow Jones Industrial, SP 500 Index, Nasdaq 100, NASDAQ Composite, NASDAQ Biotechnology, SP 100 Index, ARCA Biotechnology, SP 100, ARCA Institutional, Health Management, Drugs, Cash Cows, Baby Boomer Prospects, Macroaxis Index, Robots And Drones, Giant Impact, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAmgen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amgen's financial leverage. It provides some insight into what part of Amgen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amgen Inc (AMGN) is traded on NASDAQ Exchange in USA. It is located in One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 and employs 26,700 people. Amgen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 173.04 B. Amgen Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 537.53 M outstanding shares of which 9.37 M shares are presently shorted by private and institutional investors with about 4.62 trading days to cover.
Amgen Inc currently holds about 11.48 B in cash with 8.47 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.51.
Check Amgen Probability Of Bankruptcy
Ownership AllocationAmgen holds a total of 537.53 Million outstanding shares. The majority of Amgen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amgen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amgen. Please pay attention to any change in the institutional holdings of Amgen Inc as this could imply that something significant has changed or is about to change at the company. On October 10, 2024, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Amgen Inc's common stock.
Check Amgen Ownership Details
Amgen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Norges Bank | 2024-06-30 | 5.8 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 5.4 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 5.2 M | |
| Royal Bank Of Canada | 2024-06-30 | 5.1 M | |
| Legal & General Group Plc | 2024-06-30 | 4.8 M | |
| Hhg Plc | 2024-06-30 | 4.6 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 4.5 M | |
| Ubs Asset Mgmt Americas Inc | 2024-06-30 | 4.2 M | |
| Fmr Inc | 2024-06-30 | 4.1 M | |
| Vanguard Group Inc | 2024-06-30 | 51.9 M | |
| Blackrock Inc | 2024-06-30 | 46 M |
Amgen Historical Income Statement
Amgen Stock Against Markets
Amgen Corporate Management
| Linda Louie | VP Officer | Profile | |
| James MD | Executive Officer | Profile | |
| Nancy Grygiel | Senior Officer | Profile | |
| Justin Claeys | Vice Relations | Profile |
Already Invested in Amgen Inc?
The danger of trading Amgen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amgen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amgen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amgen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.82 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.